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Ovarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with
advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies
to improve the outcomes. Advances in understanding the role of immune system in the pathogenesis of cancer have led to the
rapid evolvement of immunotherapy, which might establish a sustained immune system response against recurring cancer cells.
Recently, it has emerged that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by
specificmolecules often called “immune checkpoints,” which turn off the immune system. Similarly, cancer cells are able to use these
checkpoints to avoid immune control and rejection. Inhibition of these inhibitory pathways represents a potent strategy in the fight
against cancer and is currently under investigation with encouraging results in some cancers, such as melanoma. In ovarian cancer
researches are still in an early phase, but with promising results. In this review we will explore the rationale of immunotherapy in
ovarian cancer with a special focus on these emerging molecules.
1. Introduction
Overview. Ovarian cancer (OC) is a common condition in
women scenario and it represents the principal cause of death
from gynaecologic cancer in United States [1]. It is estimated
that 21.290 cases will have been diagnosed in 2015 and that
14.180 women will have died due to this malignancy. About
90% of OC are epithelial carcinomas and 70% of those have a
serous histology [2]. Death rate fromOCdeclined from 1970s
to 1990s but it has since then remained stable.
In light of these discouraging data, the development of
novel therapies for OC has become a priority. Recent better
molecular characterization and immune system identifica-
tion are the starting point of future research in immunother-
apy.
Undoubtedly, the next decade will see immunotherapy
coming to the clinic use alongside standard regimes and it
is possible that it could replace cytotoxic chemotherapy in
combination strategies. Therefore, in addition to possessing
expertise with immunotherapy, oncologists will be expected
to conduct trials of novel agents in combinationwith standard
treatment. Thus, it is paramount to focus the attention on
maximising the knowledge of the more important compo-
nent of the immune system. Loss in this challenge could
run the risk that oncologists will take a passive role in the
development of new strategies.
This paper reviews the rationale for immunotherapy and
the main approaches under investigation in OC, with a
special focus on the role of checkpoint inhibitors.
We will briefly describe the human immune system in an
attempt to provide a means of understanding how it relates
specifically to the clinical practice.
2. Immune System and Cancer Disease
2.1. The Father of Immunotherapy. The role of immunother-
apy in cancer treatment has been identified decades ago,
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because of beneficial effect of severe induced infection on
tumour regression. At that time, Coley showed that inocula-
tion with streptococcal organisms resulted in the shrinkage
of inoperable bone and soft-tissue sarcomas [3]. However,
severe criticisms due to the inconsistency of the method and
results emerged in the scientific community, across the years.
One explanation was that other physicians, who tested his
treatment, did not report the same excellent effect. These
results, as well as the concurrent development of radiotherapy
and chemotherapy, determined immunotherapy to slowly
disappear from treatment cancer scenario [4]. Since Coley’s
death, immunology has represented an active research field
and, nowadays, immunotherapy is considered again a valid
treatment option in different types of cancer [5].
2.2. Basic Knowledge of Human Immune System. The human
immune system can be divided in two components: the innate
and the adaptive immunity.
The innate immune system consists of natural killer
(NK) cells, dendritic cells, andmacrophages and neutrophils,
whereas B cells and T cells, including cytotoxic (CD8+ T or
CTL) cells, helper (CD4+ T) cells, and NKT cells, are specific
of the adaptive immunity [6]. The innate immunity provides
a first line response against pathogens in a nonspecific
manner; it has no immunologic memory and it is not able
to recognize antigen. Thus, in terms of tumor immunology,
its contribution is marginal and limited to secreted cytokines
that recruit immune cells. On the other hand, the adaptive
immune system plays a central role in the antitumor immune
response, due to its capability in processing “nonself ” cells.
T cell activation requires at least two conditions. Firstly,
the presentation of an antigen to a T cell receptor (TCR)
by a major histocompatibility complex (MHC) molecule on
antigen presenting cells (APCs). Secondly, the interaction of
the CD28 receptor on T cells to B7 costimulatory molecules
(B7-1 and B7-2) on APCs [7].
Actually, the immune system often recognized the tumor
cells as “self,” because they are basically expression of patient’s
own cell types. The distinction between “self” and “nonself ”
is provided by cancer-specific antigens that are expressed by
tumor cells. Tumor antigens are traditionally divided in two
classes: tumor specific antigens (TSAs) and tumor associated
antigens (TAAs). TSAs are exclusively expressed by tumor
cells and thus they are easily recognized as “nonself ” by the
immune system. TSAs represent an ideal target for anticancer
immunotherapy. On the contrary, TAAs are normally found
on nonmalignant cells. For instance, oncospermatogonal
antigens are expressed by tumor cells as well as normal sper-
matocytes; carcinoembryonic antigen (CEA) is expressed on
fetal tissues and in several cancer types. Therefore TAAs are
less expected to activate an effective and efficient immune
system response [8].
2.3. Immunoediting Process: The 3Es of the Immune System.
Theoretically, the immune system recognizes nascent trans-
formed cells, in order to prevent progression to clinical
tumor. If intrinsic tumor suppressor mechanisms failed, the
cancer immunoediting is engaged. It is an extrinsic tumor
suppressor mechanism that consists of 3 sequential phases:
elimination, equilibrium, and escape [9].
The elimination phase was previously known as cancer
immunosurveillance. In this phase, transformed cells are rec-
ognized and eradicated by the innate and adaptive immune
system. CD8+ T cells, CD4+ T cells, natural killer (NK) cells,
and NK T cells secrete interferon- (INF-) 𝛾 to inhibit tumor
cell proliferation and angiogenesis, whereas macrophages
and dendritic cells are processed to phagocytise and remove
tumor cells killed [10].
The cells that are not eliminated in this phase may then
enter the equilibrium phase, in which their development is
prevented by adaptive immunologic mechanism. CD8+ T
cells and dendritic cells secrete INF-𝛾 and interleukin- (IL-)
12, respectively, and preserve tumor cells in a steady state.This
is a functional state in which latent tumor cells are specifically
controlled by the adaptive immunity. This dynamic balance
can persist for long period, sometimes exceeding 20 years [9].
In response to immune system, tumor cells can change
their characteristics in immune resistant cells and therefore
escape from immune system suppression. In this final phase,
tumor cells emerge and become clinically apparent, because
they are no longer blocked by immunity. The generation
of immune resistant tumor cells can occur in several ways:
through loss of tumor antigens expression; through downreg-
ulation of MHC; through the overactivation of the proonco-
genic transcription factor STAT3; through the overexpression
of antiapoptotic effector BCL-2; through the expression of
inhibitory cell surface molecules, such as programmed cell
death 1 ligand 1 (PD-L1), cytotoxic T-lymphocyte associated
protein-4 (CTLA-4), and Fas ligand (FasL), which directly kill
cytotoxic CD8+ T cells. Otherwise tumor cell escape can be
a consequence of an immunosuppressive state established in
the tumormicroenvironment.This conditionmay result from
the secretion of immunosuppressive cytokines, like IL-4,
IL-1𝛽, vascular endothelial growth factor (VEGF), and
prostaglandin-E2 (PGE2), which recruit regulatory cells.
Particularly, the secretion of IL-4 recruits macrophages that
inhibit CD4+ T cells, by expressing transforming growth
factor-𝛽 (TGF-𝛽), IL-10, and platelet-derived growth factor
(PDGF), whereas the secretion of IL-1𝛽, VEGF, and PGE2
determines the accumulation of myeloid-derived suppressor
cells that blocks T cell function [11].
2.4. The Rationale. Over the last decade immunotherapy has
become a mainstay in anticancer therapy. The aim is to erad-
icate tumor cells stimulating the normal human immune
system. We need to integrate the potential understanding of
the immunoediting process from the 3Es and the tumor char-
acteristics to conduct the optimal treatment. It is difficult
to define a clear role of immunotherapy; nonetheless it is
reasonable to hypothesise that any immunemolecule capable
of activating this process might have a useful role in erad-
ication of nascent tumor cells. At this time it is paramount
that oncologists are familiar with the immunoediting process
so that they can have a role in the rational development of
innovative clinical trials. Immunotherapy has the potential to
guide the future direction of cancer treatment.
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The stabilization of equilibrium state, as well as the inhi-
bition of tumor escape mechanisms, should be clinical end-
points.
3. Cancer Immunotherapy: The Role of
Immune Checkpoint
3.1. Current Immunotherapy Options. Current immunother-
apies for cancer treatment include therapeutic vaccines,
cytokines, immune modulators, immune checkpoint inhi-
bitors, and adoptive T cell transfer [12].
Therapeutic vaccines are designed to treat established
cancers and may be used in the induction of the tumor-
directed immune response of the patients through the intro-
duction of tumor antigens. The other approaches such as
immune checkpoint inhibitors and adoptive T cell transfer
are designed to augment anticancer immunity against cancer
[13].
3.2. Focus on ImmuneCheckpoint. Nowadays, one of themost
promising strategies seems to be the takeover of immune cell-
intrinsic checkpoints that are induced on T cells activation.
The blockade of one of these checkpoints, such as CTLA-4
[14] or the programmed death 1 (PD-1) receptor, has recently
been found to be active to achieve an immune-modulation
approach in the treatment of solid tumors [15, 16]. The
immune checkpoint blockade targeted agents might repre-
sent breakthrough drugs in the treatment of solid tumors
and have generated greater expectations in the field of cancer
immunotherapy, even in OC [17, 18].
3.3. Mechanisms of Action of Immunomodulators. T cells
activity is regulated by a great number of different molecules,
as well as immune-modulatory signals, both costimulatory
and coinhibitory [19]. To avoid inappropriate T cell activa-
tion, resulting in autoimmunity, negative regulators of T cell
immunity, including CTLA-4 and PD-1, are needed. Preclini-
cal models on the blockade of these coinhibitory molecules
showed an antitumor immune response [17]. In fact both
CTLA-4 and PD-1 are key immune checkpoint proteins and
represent a further promising immunotherapeutic target.
CTLA-4 is a member of the CD28:B7 immunoglobulin
superfamily, typically low-expressed on the surface of naive
effector T cells and regulatory T cells (Tregs) [20]. When
naive T cells are stimulated through the TCR, CTLA-4 is
upregulated and competes with CD28 for B7 and, finally,
determines the suppression of T cell activity [21]. It was
found that the antitumor effect of CTLA-4 blockademight be
obtained also by depletion of Treg [22], as revealed in amodel
of mouse melanoma, in which both the augmentation of T
effector cell function and inhibition of Treg activity through
the blockade of CTLA-4manage to obtain a strong antitumor
response.
PD-1 is expressed on chronically stimulated T cells, as
well as Tregs, activated B cells, and NK cells [23]. Differently
from CTLA-4, which regulates T-lymphocytes at the level of
initial activation, PD-1 regulates immunity at multiple phases
of the immune response, including its effect on effector
T-lymphocyte activity in the peripheral tissues. Experimental
models showed that PD-1 deficient mice present enhanced
immunity with phenotypes characterized by autoimmune
cardiomyopathy and a lupus-like syndrome [24, 25].
The activity of PD-1 is related to its interaction with
its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC) [26]. Both
ligands, especially PD-1, are expressed on many hematologic
and nonhematologic human tumors [27].
Generally, in human cancer, when PD-1 binds with cells
bearing one of its ligands, T cell activity is attenuated (phe-
nomena known as peripheral tolerance), which prevents
these T cells from rejecting the tumor at the tissue level, and
tumors can thereby employ the PD-1 inhibitory pathway to
silence the immune system [28].
4. Clinical Trials with Immune Checkpoint
Blockade Targeted Agents in OC
Based upon the findings of preclinical studies, suggesting the
involvement of these molecules in immune control, various
agents blocking CTLA-4, PD-1, or PD-L1 or other immune
molecules are currently investigated in ovarian cancer (OC)
treatment. Details are shown in Table 1.
4.1. Anticytotoxic T-Lymphocyte Antigens. The CTLA-4 is
currently being investigated as a single or combinatorial ther-
apy in clinical trials involving several cancer types.
Ipilimumab and tremelimumab are fully human IgG1 or
IgG2 antibodies, respectively, that antagonize the CTLA-4
immune checkpoint. The majority of clinical data derived
from studies in patients with melanoma. In these studies
CTLA-4 blockade has yielded objective responses to such an
extent that ipilimumab was FDA approved to treat metastatic
or unresectable melanoma in 2011 [29, 30]. It represented the
first standard-of-care immune checkpoint inhibitor.
Experience in OC is actually based on small population
studies but results seem to be interesting.
Hodi et al. firstly showed [31, 32] antitumor effects in
patients with stage IV OC patients. Initially [31], they
reported that a single infusion of ipilimumab (3mg/kg) in
two-stage IV OC patients previously vaccinated with granu-
locyte-macrophage colony-stimulating factor modified irra-
diated autologous tumor cells (GVAX), was well tolerated,
and triggered a decrease or stabilization of CA-125 levels of
several months’ duration.
In order to clarify the toxicity and antitumor efficacy,
they treated additional 9-stage IV OC subjects by using the
same antibody dose and schedule (with the exception of
one patient) [32]. In one patient, an objective radiographic
response was noted and multiple infusions of anti-CTLA-4
antibody every 3 to 5months havemaintained disease control
over 4 years; furthermore, 3 out of 9 patients had stable
disease of 6 (ongoing at the moment of paper’s publication),
4, and 2 months’ duration, as measured by CA-125 levels and
radiographic criteria, in the absence of serious toxicities.
Fewpatients showedmanageable inflammatory toxicities.
Tumor regression correlated with the CD8+/Treg ratio, sug-
gesting that other forms of therapy that target Treg depletion
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Table 1: Active trials of checkpoint inhibitor in ovarian cancer.
Drug Antibody type∗ Notable side effects Study (phase)
Anti-CTLA-4 antibodies
Ipilimumab IgG1 Diarrhea, colitis, fatigue,transaminitis, hypophysitis. I; II
Tremelimumab IgG2 Diarrhea, fatigue, nausea,vomiting, anorexia, rash I
Anti-PD-1 antibodies
Nivolumab IgG4 Pneumonitis, lymphopenia, fatigue,diarrhea, hepatitis, renal insufficiency I; II
Pembrolizumab IgG4-kappa Pneumonitis, fatigue, thyroid problems I
Anti-PD-L1 antibodies
BMS-936559 IgG4
Fatigue, hyperglycemia, infusion reaction,
endocrinopathies, adrenal insufficiency, myasthenia
gravis
I; II
MEDI4736 IgG1-kappa Diarrhea, fatigue, rash, vomiting I
MPDL33280A IgG4 Hyperglycemia, hypophysitis, pericardial effusion,fatigue I
MSB0010718C IgG1 Laboratory abnormalities, creatine kinase increase,myositis, myocarditis I; II
∗All fully human, except pembrolizumab which is a humanized IgG4-kappa.
Updated on February 28, 2015.
might have a synergistic effect when combined with the
tumor vaccine and CTLA-4 antibody molecules.
These findings prompted a phase II clinical trial to eval-
uate ipilimumab as monotherapy in platinum-resistant OC
patients (NCT01611558) [33]. Ipilimumab can cause signif-
icant immune-related adverse events (AEs), and the more
common observed side effects include diarrhea, colitis, and
dermatitis. Less common severe immune-related adverse
events include hypophysitis, thyroiditis, and hepatitis.
Tremelimumab (previously known as ticilimumab) is a
fully human IgG2 monoclonal antibody to CTLA-4. In con-
trast to ipilimumab, a large phase III trial [34] in melanoma
did not demonstrate improved PFS or OS compared with
cytotoxic chemotherapy although durable responses were
observed in some patients. Much speculation have been done
about the potential reasons for this clinical result, because
both phase III clinical trials [14, 29] testing ipilimumab suc-
ceeded in showing improved OS. It has been proposed that
human IgG1 (the ipilimumab subclass) binds with a higher
affinity to Fc𝛾Rs than human IgG2 (the subclass of tremeli-
mumab) does [35], therefore suggesting that tremelimumab
might determine a CTLA-4 antibody mediated Treg-cell
depletion to a lesser extent [36, 37]. The combination of
tremelimumab and a PD-1 inhibitor (see below) is currently
ongoing, in a phase I study including ovarian and cervical
cancer patients [38].
4.2. PD-1 and PD-L1 Targeting Agents. The therapeutic bene-
fit obtained with CTLA-4 inhibition led to the effort in iden-
tifying other potential immune checkpoint inhibitors that
should have been more specific and equally efficacious and
have less immune toxicity. PD-1 and PD-L1 inhibitors were
identified as potentially accomplishing those requirements.
Differently from CTLA-4, which regulates T-lymphocytes at
the level of initial activation, PD-1 regulates immunity at
multiple steps, including exerting its effect on effector T-
lymphocyte activity in the peripheral tissues. Several mon-
oclonal antibodies have been developed that block the PD-1
system, either by interactions with the PD-1 receptor or with
its specific ligands.
Nivolumab (also known as BMS-936558 or MDX1106) is
a fully human IgG4 monoclonal antibody that targets PD-1.
A phase I/II clinical trial [39] tested the safety and efficacy
of nivolumab at doses of 0.1 to 10.0mg/kg of body weight
intravenously every 2 weeks for up to 12 cycles until disease
progression or a complete response occurred. Patients with
advanced melanoma, non-small-cell lung cancer, prostate
cancer, renal cancer, and colorectal cancer were enrolled.
Among the 296 patients, those with metastatic melanoma
achieved the higher rates of objective responses (27.6%), with
a median OS of 16.8 months; conversely responses were not
observed in colon and prostate cancer patients. Responses
were seen in both PD-L1 positive and negative patients,
even if with lower extent. Common treatment-related adverse
events included fatigue, diarrhea, pruritus, rash, nausea, and
decreased appetite. Grade 3 or 4 treatment-related adverse
events were seen in 14%of patients. Treatment-related serious
adverse events were noted in 11% of patients and included
pneumonitis (3%, and grade 3 or 4 in 1%), colitis, hepatitis,
thyroiditis, and hypophysitis.
Recently, at the 2014 ASCO meeting [40], the first clin-
ical trial of nivolumab treatment against platinum-resistant
OC has been presented. A total of 18 evaluable patients
were treated with nivolumab: 10 patients were administered
1mg/kg and 8 patients were administered 3mg/kg, each every
2 weeks for 1 year. Starting at week 8, patients were assessed
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every 8 weeks and patients with disease progression were
taken off study. Median treatment duration was 14 weeks.
There were two serious treatment-related AEs: one patient in
the 1mg/kg group experienced grade 3 fever, disorientation,
and gait disorder and one patient in the 3mg/kg category
experienced grade 3 fever and deep-vein thrombosis. Other
grade 3/4 treatment-related AEs included hypothyroidism
(two patients, both in the 1mg/kg group); heart arrhythmia
(one patient, in the 3mg/kg group); and lymphocytope-
nia (one patient, in the 1mg/kg group). Interestingly, the
overall objective response rate was 17%. The 3mg/kg dose
may be more favourable (25%) than 1mg/kg (10%). Two
patients in the 3mg/kg group experienced complete response
(CR; response rate 25%). Among those receiving 1mg/kg
nivolumab, one experienced a partial response (10% response
rate) and two patients experienced stable disease (SD).
Further researches are investigating biomarkers predicting
response.
A further molecule investigated in OC is pembrolizumab
(MK-3475, formerly known as lambrolizumab), a humanized
IgG4 monoclonal antibody against PD-1. It was found to be
active in treating both melanoma and NSCLC [41–43], simi-
lar to nivolumab. Actually, no randomized trial has compared
the two agents, which are surely different in binding affinities,
nivolumab being a fully human IgG4, and pembrolizumab
is humanized. Currently, phase I trials are ongoing with
both molecules including OC patients. Recently, an interim
analysis with pembrolizumab showed preliminary signal for
clinical efficacy in recurrent OC [44].
In addition to antibodies targeting PD-1, several different
anti-PD1-L1 monoclonal antibodies, such as BMS-936559,
MPDL3280A, MEDI4736, and MSB0010718C, have been
developed which might enhance immune function. It was
found that the ligand/receptor interaction inhibits the T-lym-
phocyte response by inhibiting the kinases involved in T-
lymphocyte activation via phosphatase activity and other
signaling pathways [45].
BMS-936559 is a high-affinity, fully human IgG4 mono-
clonal antibody that binds PD-L1 and that blocks PD-L1 from
binding its two known receptors PD-1 and CD8.
It was safe in a phase I trial that included 17 OC patients
[15] in escalating doses of 0.3–10mg/kg iv every 14 days in 6-
week cycles for up to 16 cycles or until the patient had
a complete response or confirmed disease progression and
observed durable tumor regression and prolonged stabi-
lization of disease. Common side effects included fatigue,
infusion reactions, diarrhea, arthralgia, pruritis, rash, nausea,
and headache. In the trial, only OC patients at the 10mg/kg
dose achieved objective responses: 1 (6%) with a partial
response and 3 (18%) with stable disease lasting more than
24 weeks.
MSB0010718C is a fully human IgG1 monoclonal anti-
body targeting PD-L1. Unlike other PD-L1 targeting agents,
it is a native Fc receptor, allowing for antibody dependent cell
mediated cytotoxicity.
In a phase I trial [46] 27 patients with refractory malig-
nancies were treatedwithMSB0010718C at 1, 3, 10, and 20mg/
kg twice weekly. Eleven patients in the study had received
prior treatment with an immunotherapy. At the 3 and
10mg/kg doses, the drug was found to inhibit 93.8% and
93.2% of the PD-L1 receptor on peripheral leukocytes. Addi-
tionally, a linear PK profile was found, with a maximum
concentration of the drug achieved at 1.5–2 hours following
infusion. At the 20mg/kg dose, a dose-limiting immune-
related adverse event was noted. In this trial also OC patients
were included and, interestingly, a larger subsequent meta-
analysis of the company developing the drug (Merck) [47],
including 23 patients’ OC cohort, showed 48% of patients
reaching stable disease and 17% getting a partial response
within 30 weeks of treatment start, though 13 had been
taken off the drug. Noteworthily, the responses came despite
77% of patients having already failed at least three lines of
therapy. More recently [48], efficacy data from the 23 patients
followed up formore than 2months (range 2–8months) were
presented. Four patients (17.4%) achieved an unconfirmed
partial response, 11 (47.8%) patients had stable disease, and
2 patients had >30% tumor shrinkage after progression.
Median PFS was 11.9 weeks and the PFS rate at 24 weeks was
33.3%. Toxicity was manageable and only 2 patients (8.7%)
experienced grade≥ 3 drug-relatedAEs.Themost commonly
reported AEs were fatigue, nausea, and diarrhea. A larger,
phase II clinical trial enrolling 590 patients is ongoing.
Other molecules, such as MPDL3280A and MEDI4736,
are currently investigated in phase I trials including OC
patients.
4.3. Concluding Remarks. OC is defined as an immuno-
genic tumor that exhibits a spontaneous antitumor immune
response [49]. Tumor tissue can be considered a Darwinian
microenvironment that selects the better strategy to elude the
immune system. Immune checkpoint pathways are modu-
lated by ligand/receptor interactions. Expression of specific
ligands, such as PD-L1 and CTLA-4, in the stroma or in the
tumor cells associated, is paramount to improve growth and
resistance to immune attack. It depends on both tumor type
and histology, and therefore it also represents the major
limitation of immunotherapy. Maybe the identification and
characterization of similar patients population, as well as
tumor histology, could provide data to facilitate the devel-
opment of novel treatment strategies. Immune check point
inhibitors may have a synergic mechanism in multimodality
treatment and thus a positive effect on overall survival, with
a tolerable toxicity profile. Further randomized trials are
paramount to prospectively clarify this hypothesis.
5. Conclusions
In the last years, immunotherapy has achieved an important
role in the fight against cancer and also, inOC immunological
phenomena, has been demonstrated to play a central role.
Novel and promising agents have been developed.
Immune checkpoint inhibitors have shown clinical activity
in several cancers, especially melanoma, and they represent
a major step forward in the fight against cancer.
These novel therapies will likely play a role also in OC
given the potential for rapid, durable responses and their
favourable toxicity profiles. Their function in the treatment
of patients with OC remains to be defined but initial results
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seem to be promising. Next challenges should be the clinical
development of combinatorial approaches and further defin-
ing patientswho benefit from immune checkpointmonother-
apy and patients who require potentially more active albeit
more toxic combination regimens. Finally, the definition
of potential biomarkers that can determine which immune
checkpoint pathway or pathways dominate in a particular
tumor will be crucial to guide the choice of inhibitor.
The possibility of using immunotherapy in OC is still
restricted to clinical trials but it is reasonable to expect that
over the next years important advances in OC immunother-
apy will be made, running further phase II and III trials
development.
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